Liquidia (NASDAQ:LQDA) Announces Earnings Results

Liquidia (NASDAQ:LQDA - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08), Zacks reports. The business had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

Liquidia Trading Down 2.1 %

Shares of LQDA stock traded down $0.32 during mid-day trading on Friday, reaching $15.12. The stock had a trading volume of 1,056,985 shares, compared to its average volume of 934,542. The stock's 50-day moving average price is $14.79 and its two-hundred day moving average price is $12.23. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.92. The firm has a market capitalization of $1.28 billion, a PE ratio of -9.28 and a beta of 0.07.

Insider Buying and Selling at Liquidia

In other news, General Counsel Russell Schundler sold 16,393 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the sale, the general counsel now owns 573,478 shares of the company's stock, valued at approximately $6,755,570.84. The trade was a 2.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the sale, the insider now directly owns 270,388 shares in the company, valued at $3,185,170.64. The trade was a 2.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is currently owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LQDA shares. HC Wainwright reiterated a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday. Scotiabank lifted their target price on shares of Liquidia from $30.00 to $34.00 and gave the stock a "sector outperform" rating in a research report on Thursday. Wells Fargo & Company started coverage on shares of Liquidia in a research report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price on the stock. Finally, Needham & Company LLC lifted their target price on shares of Liquidia from $19.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia currently has a consensus rating of "Buy" and an average price target of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).